Ikonisys presents an update of its global activity in the context of its recent technological and commercial milestones
31 Juli 2023 - 7:30AM
Business Wire
Regulatory News:
Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic: ALIKO),
a company specializing in the early and accurate detection of
cancer with a unique fully-automated solution for medical
diagnostic labs, presents an overview and update of its activity
following its last successful developments since the beginning of
the year.
In the first half of 2023, Ikonisys reinforced its R&D
strategy, notably in the Circulating Tumor Cells (CTC) where the
Company has developed and is implementing a new dedicated software,
and in AI, thanks also to the first outcome of the collaboration
with Polytechnic of Milano. Ikonisys will continue its efforts and
has high expectations for its future CTC solutions, supported by
its proven ability to transform R&D investments into concrete
commercial advances, as demonstrated by the recent sales of the
Ikoniscope20max. The installations in two important urology
laboratories in the US, and the validation of the first instrument
installed are the result of the technical and operational
specificities of the Ikoniscope20max which have been effectively
fine-tuned by the R&D team thanks also to the strategic
partnerships initiated in the past years.
With the signature of a distribution agreement with Integrated
Gulf Biosystems Group for the sale of the solutions in the Middle
Eastern and India markets, as previously announced, and the initial
commercialization of the Ikoniscope20max in the US, the Company has
now reached important milestones in its commercial strategy.
Taking into account these successful developments, the Company
is now having ongoing discussions with industry players with
presence in both Europe and USA to establish potential commercial
partnerships aiming at distributing globally an integrated solution
(including Ikonisys’ products) to provide an end-to-end platform
covering the entire laboratory’s workflow, from processing to
analysis, including reagents. This strategy perfectly matches the
Company’s mission of simplifying the life of technicians and
physicians to support the earlier detection of cancer cells.
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230730618591/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Aurélie Manavarere/Louis-Victor Delouvrier
Investor Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Ikonisys (EU:ALIKO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024